September 11, 2023
Purdue research: Liquid biopsy method may reveal signs of Parkinson’s disease in urine samples
A Purdue University research group led by biochemistry professor W. Andy Tao collaborated with Tymora Analytical Operations, The Michael J. Fox Foundation for Parkinson's Research and Columbia University for a study that found a non-invasive way to potentially detect Parkinson’s disease in a patient’s urine.
Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease
Roy Alcalay, associate professor, Clinical Neurology (Columbia University)
Marco Hadisurya, PhD student, Biochemistry
Anton Iliuk, president and chief technology officer, Tymora Analytical Operations
Kananart Kuwaranancharoen, PhD student, Electrical and Computer Engineering
Zheng-Chi Lee, West Lafayette Junior/Senior High School
Li Li, Tymora Analytical Operations
Shalini Padmanabhan, vice president of discovery and translational research, The Michael J. Fox
Foundation for Parkinson's Research
Andy Tao, professor, Biochemistry
Xiaofeng Wu, postdoctoral researcher, Analytical Chemistry
Communications Medicine, 2023
A team led by researchers at Purdue University and Purdue spinoff company Tymora Analytical Operations has developed a noninvasive technique that may reveal signs of Parkinson’s disease in urine samples. The researchers analyzed urine samples from 138 individuals and found several proteins involved in PD development that could be biological indicators for early detection of the disease. The method could eventually lead to widespread noninvasive testing for other neurodegenerative conditions as well as cancer. Parkinson’s disease alone affects an estimated 1% of the over-60 population. Up to a million Americans live with the disease, while 90,000 new cases are diagnosed each year.